Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders

@article{Bchir2007AnxiolyticTW,
  title={Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders},
  author={Markus B{\'e}chir and Kyrill Schwegler and R{\'e}my Chenevard and Christian Binggeli and Christian Caduff and Stefan B{\"u}chi and Claus Buddeberg and Thomas Felix L{\"u}scher and Georg Noll},
  journal={Autonomic Neuroscience},
  year={2007},
  volume={134},
  pages={69-73}
}

Anxiolytic medication use is not associated with anxiety level and does not reduce complications after acute myocardial infarction.

Use of anxiolytic medication in patients with AMI was not associated with anxiety level and did not reduce the probability of in-hospital complications, and clinical guidelines for the management of patients with an AMI should address anxiety assessment and appropriate use of anxIOlytics to improve patients' outcomes.

Sympathetic Neural Control in Humans with Anxiety-Related Disorders.

This article assesses behavioral and lifestyle modifications that have been shown to concurrently improve anxiety symptoms, as well as sympathetic control, and examines the link between anxiety and cardiovascular risk.

Effects of anesthetic and sedative agents on sympathetic nerve activity.

Early Onset Neurocirculatory Response to Static Handgrip is Associated with Greater Blood Pressure Variability in Women with Post-Traumatic Stress Disorder.

The results suggest that early onset exercise pressor response in women with PTSD may be attributed to enhanced mechano- rather than metabo-reflexes and it might contribute to the mechanisms underlying the link between PTSD and cardiovascular risk.

Sympathetic Nervous System Evaluation and Importance for Clinical General Anesthesia

This review evaluates different methods for deter- mination of sympathetic nervous system activity and describes its role in human neurohumoral circulatory control.

Sympathetic Nervous System: Evaluation and Importance for Clinical General Anesthesia

A review of different methods for determination of sympathetic nervous system activity and its role in human neurohumoral circulatory control is described and its relevance for clinical anesthesia is discussed.

A Comprehensive Review of the Analytical Development and Validation of Alprazolam in Bulk and Pharmaceutical Dosage Form

Alprazolam is approved in 2003 by US FDA. Alprazolam is available as an extended-release tablet, a mouth dissolving tablet (a tablet that dissolves rapidly in the mouth), as well as a concentrated

Stability studies of alprazolam tablets: effects of chemical interactions with some excipients in pharmaceutical solid preparations

An HPLC method was developed to determine the stability of alprazolam (AL) as a pure drug and in monodrug pharmaceutical tablets. The main degradation product of AL tablets was isolated and fully

Pharmacological significance of triazole scaffold

This paper is an attempt to review the pharmacological activities reported for triazole derivatives in the current literature with an update of recent research findings on this nuclei.

Triazole analogues as potential pharmacological agents: a brief review

This review focuses on recent synthetic procedure of triazole moiety, which comprises of various pharmacological activities such as antimicrobial, anticonvulsant, anti-inflammatory, analgesic, antitubercular, anthelmintic, antioxidant, antimalarial, antiviral, etc.

References

SHOWING 1-10 OF 26 REFERENCES

Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study

Alprazolam at dosages between 0.25 and 3 mg/day was found to be significantly better than placebo in the treatment of either panic disorder or generalized anxiety or panic disorder.

Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks.

Whole-body and regional sympathetic nervous activity are not elevated at rest in patients with panic disorder, possibly due to loading of cardiac neuronal stores by uptake from plasma during surges of epinephrine secretion in panic attacks.

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

Alprazolam was found to be effective and well tolerated in patients with agoraphobia with panic attacks and panic disorder and significantly more placebo recipients subsequently dropped out of the trial, primarily citing ineffectiveness of placebo as the reason.

Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder.

Subjective anxiety responses after flumazenil infusion were significantly higher in the patient group with panic disorder than in the controls, and eight patients withpanic disorder but no controls had panic attacks.

Lorazepam reduces cardiac vagal modulation in normal subjects.

The significant heart rate increase and HPV decreases demonstrate vagolytic effects of LZ in healthy subjects during 24 hours of normal physiologic activity in human volunteers in the presence of steady-state LZ.

Sympathetic and cardiac baroreflex function in panic disorder

Increased reactivity of vasoconstricting sympathetic nerves may be a trait characteristic in patients with panic disorder, and any clinical significance this observation might have in relation to increased cardiac risk in panic disorder or to concordance with essential hypertension remains to be elucidated.

Sympathetic nervous system activity in panic disorder

The stress-, but not corticotropin-releasing hormone-induced activation of the pituitary-adrenal axis in man is blocked by alprazolam.

The effects of the triazolobenzodiazepine alprazolam on both the stress- and CRH-induced changes in ACTH, cortisol, and prolactin secretion were investigated in ten healthy volunteers.